Bioheart Inc (BHRT) 0.0029 $BHRT Bioheart, Inc.
Post# of 273318
Posted On: 08/18/2016 3:11:02 PM
Bioheart Inc (BHRT) 0.0029 $BHRT
Bioheart, Inc. Completes ClearIt and Magna Deals
ACCESSWIRE - Fri Oct 02, 3:00PM CDT
SUNRISE, FL / ACCESSWIRE / October 2, 2015 / U.S. Stem Cell, Inc., a Florida corporation, (in transition from Bioheart, Inc. (OTCQB: BHRT)) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce the completion of important transactions with ClearIt, LLC and Magna Equities II, LLC ("Magna"
.
US STEM CELL (Bioheart) Announces Insiders Intend to Purchase Company Common Stock in the Open Market
ACCESSWIRE - Thu Sep 17, 12:41PM CDT
SUNRISE, FL / ACCESSWIRE / September 17, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (OTCQB: BHRT)) announces today that "insiders" led by Dr. William P. Murphy, Jr., Chairman and Mike Tomas, President and CEO, intend to purchase, in the open market, up to 5% of the issued and outstanding Common Stock of the Company. The planned insider purchases are subject to customary restrictions based upon any of the participant's knowledge of material non-public information and are further subject to federal securities disclosure rules. As the planned insider purchases are to be executed by individuals, US STEM CELL cannot guarantee the number of shares to be purchased or the time frame in which these shares will be bought in the open market.
Kristin Comella, US STEM CELL (Bioheart) CSO, Speaks at World Stem Cell and Regenerative Medicine Congress
ACCESSWIRE - Mon Sep 14, 11:10AM CDT
SUNRISE, FL / ACCESSWIRE / September 14, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (OTCQB: BHRT)) - As a recognized scientific leader and patient advocate, Kristin Comella, US STEM CELL's Chief Scientific Officer, was a top speaker at this year's annual World Stem Cell and Regenerative Medicine Congress, which was held in Washington, DC on September 2nd and 3rd. From the many presentations on technological advancements and clinical achievements in stem cell therapeutics and regenerative medicine, Ms. Comella's presentation highlighted the immediate health benefits and practical business implications of her work in launching the US Stem Cell Clinic and US Stem Cell Training business.
Bioheart Reports Continuing Financial Achievements in First Half and Second Quarter 2015 Results
ACCESSWIRE - Tue Aug 18, 8:01AM CDT
SUNRISE, FL / ACCESSWIRE / August 18, 2015 / Bioheart, Inc. (OTCQB: BHRT) announces today its continuing achievements in its first half and second quarter 2015 balance sheet positions and performance results from operations. Of specific note are the following highlights:
Bioheart CEO Tomas Voted Top Entrepreneur
ACCESSWIRE - Mon Jun 08, 8:01AM CDT
SUNRISE, FL / ACCESSWIRE / June 8, 2015 / Bioheart, Inc., a Florida Corporation (OTC:BHRT) announces today that Mike Tomas, President and CEO of Bioheart, Inc. was voted by the Miami Today newspaper editorial board, in its June 4, 2015 special edition, as one of Miami's top entrepreneurs: Miami Today, June 4, 2015: The Best of Miami 2015; Best of entrepreneurs find opportunity, play in the unknown.
Bioheart Enters Agreement to Acquire Pavillion Scientific
ACCESSWIRE - Wed Jun 03, 8:02AM CDT
SUNRISE, FL / ACCESSWIRE / June 3, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it has entered into an letter of intent to acquire Pavillion Scientific, Inc. (Florida) a wholly owned subsidiary of Pavillion Foods, Inc. (Florida). Pavillion Scientific is the provider of stem cell collection kits to both Bioheart, Inc and Vetbiologics. Management believes that the acquisition of Pavillion Scientific by Bioheart will enable Bioheart and Vetbiologics to significantly reduce their cost of goods sold and correspondingly increase their gross margin on sales. Under the terms of the letter of intent, Pavillion Foods, Inc. will receive cash, future royalties on a defined number of unit sales and Bioheart Common Stock warrants to purchase Bioheart Common Stock at a predetermined price. Upon completion of a Definitive Agreement, of which there are no assurances will be consummated, Pavillion Scientific will become an operating division of Bioheart, Inc.
Bioheart Chairman Affirms Corporate Strategy Through Stock Purchase - REVISED
ACCESSWIRE - Sat May 23, 10:44AM CDT
Untitled Document
Bioheart Chairman Affirms Corporate Strategy Through Stock Purchase
ACCESSWIRE - Fri May 22, 12:52PM CDT
SUNRISE, FL / ACCESSWIRE / May 22, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that Dr. William P. Murphy, Jr., Bioheart's Chairman purchased 2,873,564 shares of Bioheart Common Stock in an open market transaction valued at $28,735.64 or $0.01 per share. The purchase of Bioheart Common Stock by Dr. Murphy was made at a premium to Bioheart's currently trading price per share. Subsequent to the purchase, Dr. Murphy owns 16,016,412 shares of Bioheart Common Stock.
Bioheart Highlights Positive First Quarter Results
ACCESSWIRE - Wed May 06, 7:02AM CDT
SUNRISE, FL / ACCESSWIRE / May 6, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) highlights today the positive results from its first quarter 2015 operations:
Kristin Comella, CSO Blogs with Paul Knoepfler on Bioheart and US Stem Cell Clinic and Training
ACCESSWIRE - Wed Apr 22, 8:02AM CDT
SUNRISE, FL / ACCESSWIRE / April 22, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB) announces today that Kristin Comella's blog interview with Paul Knoepfler, the Knoepfler Lab Stem Cell Blog is available on line through the following link:
Bioheart Posts Contact Information for its Upcoming Conference Call
ACCESSWIRE - Mon Apr 20, 11:17AM CDT
SUNRISE, FL / ACCESSWIRE / APRIL 20, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today the following contact information for its 1st Quarter Preview Conference Call to be held on Thursday, April 23rd at 4:30 EDT. Participants can join the call through the Company's GoToMeeting portal or by phone using the following links:
US Stem Cell Clinic Increases Staff to Support Patient Demand and Marketing
ACCESSWIRE - Thu Apr 16, 11:01AM CDT
SUNRISE, FL / ACCESSWIRE / April 16, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that its US Stem Cell Clinic division has increased its staff to support increasing patient demand and the creation and launch of new marketing initiatives.
Bioheart to Preview Positive 1st Quarter Results in Upcoming Conference Call
ACCESSWIRE - Wed Apr 15, 11:20AM CDT
SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
Bioheart and Ascyrus Medical Execute Investment Agreement
ACCESSWIRE - Thu Mar 19, 8:31AM CDT
SUNRISE, FL / ACCESSWIRE / March 19, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.
Bioheart Touts 2014 Accomplishments; Seeks More in 2015
ACCESSWIRE - Tue Mar 17, 1:27PM CDT
SUNRISE, FL / ACCESSWIRE / March 17, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics, Inc.
ACCESSWIRE - Wed Feb 11, 10:18AM CST
SUNRISE, FL / ACCESSWIRE / February 11, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today the appointment of Martin E. Schmieg as President of Vetbiologics, Inc., the Company's wholly owned animal health subsidiary.
Bioheart Updates and Diversifies Its Clinical Development Pipeline
ACCESSWIRE - Thu Jan 29, 9:00AM CST
SUNRISE, FL / ACCESSWIRE / January 29, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today an update and diversification plan for its clinical development pipeline. The company's update includes a realignment of its cardiovascular product candidates and diversification into the treatment of autoimmune diseases with a first generation, investigational research program to treat Rheumatoid Arthritis (RA).
Bioheart Confirms Date and Access for Shareholder Conference Call
ACCESSWIRE - Wed Jan 28, 9:00AM CST
Strategic Direction for 2015 and Forward to be Highlighted
Bioheart, Inc. Completes ClearIt and Magna Deals
ACCESSWIRE - Fri Oct 02, 3:00PM CDT
SUNRISE, FL / ACCESSWIRE / October 2, 2015 / U.S. Stem Cell, Inc., a Florida corporation, (in transition from Bioheart, Inc. (OTCQB: BHRT)) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce the completion of important transactions with ClearIt, LLC and Magna Equities II, LLC ("Magna"
. US STEM CELL (Bioheart) Announces Insiders Intend to Purchase Company Common Stock in the Open Market
ACCESSWIRE - Thu Sep 17, 12:41PM CDT
SUNRISE, FL / ACCESSWIRE / September 17, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (OTCQB: BHRT)) announces today that "insiders" led by Dr. William P. Murphy, Jr., Chairman and Mike Tomas, President and CEO, intend to purchase, in the open market, up to 5% of the issued and outstanding Common Stock of the Company. The planned insider purchases are subject to customary restrictions based upon any of the participant's knowledge of material non-public information and are further subject to federal securities disclosure rules. As the planned insider purchases are to be executed by individuals, US STEM CELL cannot guarantee the number of shares to be purchased or the time frame in which these shares will be bought in the open market.
Kristin Comella, US STEM CELL (Bioheart) CSO, Speaks at World Stem Cell and Regenerative Medicine Congress
ACCESSWIRE - Mon Sep 14, 11:10AM CDT
SUNRISE, FL / ACCESSWIRE / September 14, 2015 / US STEM CELL, Inc. (in transition from Bioheart, Inc. (OTCQB: BHRT)) - As a recognized scientific leader and patient advocate, Kristin Comella, US STEM CELL's Chief Scientific Officer, was a top speaker at this year's annual World Stem Cell and Regenerative Medicine Congress, which was held in Washington, DC on September 2nd and 3rd. From the many presentations on technological advancements and clinical achievements in stem cell therapeutics and regenerative medicine, Ms. Comella's presentation highlighted the immediate health benefits and practical business implications of her work in launching the US Stem Cell Clinic and US Stem Cell Training business.
Bioheart Reports Continuing Financial Achievements in First Half and Second Quarter 2015 Results
ACCESSWIRE - Tue Aug 18, 8:01AM CDT
SUNRISE, FL / ACCESSWIRE / August 18, 2015 / Bioheart, Inc. (OTCQB: BHRT) announces today its continuing achievements in its first half and second quarter 2015 balance sheet positions and performance results from operations. Of specific note are the following highlights:
Bioheart CEO Tomas Voted Top Entrepreneur
ACCESSWIRE - Mon Jun 08, 8:01AM CDT
SUNRISE, FL / ACCESSWIRE / June 8, 2015 / Bioheart, Inc., a Florida Corporation (OTC:BHRT) announces today that Mike Tomas, President and CEO of Bioheart, Inc. was voted by the Miami Today newspaper editorial board, in its June 4, 2015 special edition, as one of Miami's top entrepreneurs: Miami Today, June 4, 2015: The Best of Miami 2015; Best of entrepreneurs find opportunity, play in the unknown.
Bioheart Enters Agreement to Acquire Pavillion Scientific
ACCESSWIRE - Wed Jun 03, 8:02AM CDT
SUNRISE, FL / ACCESSWIRE / June 3, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it has entered into an letter of intent to acquire Pavillion Scientific, Inc. (Florida) a wholly owned subsidiary of Pavillion Foods, Inc. (Florida). Pavillion Scientific is the provider of stem cell collection kits to both Bioheart, Inc and Vetbiologics. Management believes that the acquisition of Pavillion Scientific by Bioheart will enable Bioheart and Vetbiologics to significantly reduce their cost of goods sold and correspondingly increase their gross margin on sales. Under the terms of the letter of intent, Pavillion Foods, Inc. will receive cash, future royalties on a defined number of unit sales and Bioheart Common Stock warrants to purchase Bioheart Common Stock at a predetermined price. Upon completion of a Definitive Agreement, of which there are no assurances will be consummated, Pavillion Scientific will become an operating division of Bioheart, Inc.
Bioheart Chairman Affirms Corporate Strategy Through Stock Purchase - REVISED
ACCESSWIRE - Sat May 23, 10:44AM CDT
Untitled Document
Bioheart Chairman Affirms Corporate Strategy Through Stock Purchase
ACCESSWIRE - Fri May 22, 12:52PM CDT
SUNRISE, FL / ACCESSWIRE / May 22, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that Dr. William P. Murphy, Jr., Bioheart's Chairman purchased 2,873,564 shares of Bioheart Common Stock in an open market transaction valued at $28,735.64 or $0.01 per share. The purchase of Bioheart Common Stock by Dr. Murphy was made at a premium to Bioheart's currently trading price per share. Subsequent to the purchase, Dr. Murphy owns 16,016,412 shares of Bioheart Common Stock.
Bioheart Highlights Positive First Quarter Results
ACCESSWIRE - Wed May 06, 7:02AM CDT
SUNRISE, FL / ACCESSWIRE / May 6, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) highlights today the positive results from its first quarter 2015 operations:
Kristin Comella, CSO Blogs with Paul Knoepfler on Bioheart and US Stem Cell Clinic and Training
ACCESSWIRE - Wed Apr 22, 8:02AM CDT
SUNRISE, FL / ACCESSWIRE / April 22, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB) announces today that Kristin Comella's blog interview with Paul Knoepfler, the Knoepfler Lab Stem Cell Blog is available on line through the following link:
Bioheart Posts Contact Information for its Upcoming Conference Call
ACCESSWIRE - Mon Apr 20, 11:17AM CDT
SUNRISE, FL / ACCESSWIRE / APRIL 20, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today the following contact information for its 1st Quarter Preview Conference Call to be held on Thursday, April 23rd at 4:30 EDT. Participants can join the call through the Company's GoToMeeting portal or by phone using the following links:
US Stem Cell Clinic Increases Staff to Support Patient Demand and Marketing
ACCESSWIRE - Thu Apr 16, 11:01AM CDT
SUNRISE, FL / ACCESSWIRE / April 16, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that its US Stem Cell Clinic division has increased its staff to support increasing patient demand and the creation and launch of new marketing initiatives.
Bioheart to Preview Positive 1st Quarter Results in Upcoming Conference Call
ACCESSWIRE - Wed Apr 15, 11:20AM CDT
SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB: BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
Bioheart and Ascyrus Medical Execute Investment Agreement
ACCESSWIRE - Thu Mar 19, 8:31AM CDT
SUNRISE, FL / ACCESSWIRE / March 19, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT) and Ascyrus Medical, LLC, a Florida Limited Liability Corporation are pleased to announce that they have entered into an investment agreement. The investment agreement provides for Bioheart to obtain a consolidating ownership stake in Ascyrus Medical upon the achievement of certain business milestones. Bioheart has through June 30, 2015 to meet its milestone obligations.
Bioheart Touts 2014 Accomplishments; Seeks More in 2015
ACCESSWIRE - Tue Mar 17, 1:27PM CDT
SUNRISE, FL / ACCESSWIRE / March 17, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry is pleased to announce, following the release of its Form 10-K Annual Report, key 2014 accomplishments including but not limited to:
Bioheart Strengthens Management Team with Appointment of Martin E. Schmieg as President of Vetbiologics, Inc.
ACCESSWIRE - Wed Feb 11, 10:18AM CST
SUNRISE, FL / ACCESSWIRE / February 11, 2015 / Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today the appointment of Martin E. Schmieg as President of Vetbiologics, Inc., the Company's wholly owned animal health subsidiary.
Bioheart Updates and Diversifies Its Clinical Development Pipeline
ACCESSWIRE - Thu Jan 29, 9:00AM CST
SUNRISE, FL / ACCESSWIRE / January 29, 2015 / Bioheart, Inc., a Florida Corporation (OTCQB:BHRT), an emerging enterprise in the regenerative medicine / cellular therapy industry announced today an update and diversification plan for its clinical development pipeline. The company's update includes a realignment of its cardiovascular product candidates and diversification into the treatment of autoimmune diseases with a first generation, investigational research program to treat Rheumatoid Arthritis (RA).
Bioheart Confirms Date and Access for Shareholder Conference Call
ACCESSWIRE - Wed Jan 28, 9:00AM CST
Strategic Direction for 2015 and Forward to be Highlighted
(0)
(0)